Taiwan is poised to play a pivotal role in advancing the global bioscience arena, emphasizing collaboration, innovation, and resilience. The country strives to promote early-stage research, secure funding, and improve supply chain stability to achieve progress in the global healthcare sector. With its growing influence, Taiwan is strengthening its efforts in the global healthcare sphere, where a number of locally developed drugs have successfully entered international markets.
At BIO Asia-Taiwan 2025, Taiwan emphasized its commitment to fostering partnerships and advancing precision medicine, as well as its position as a hub for medical innovation and sustainable healthcare.
The BIO Asia–Taiwan 2025 convention, themed "Next Wave of Biotech Opportunities," unravelled from July 23 to 27 at the Taipei Nangang Exhibition Center, TaiNEX 1. Spanning two floors, the event featured 23 themed zones showcasing the entire biomedical value chain, reinforcing its position as Asia's largest platform for biotech collaboration and innovation. With a record-breaking 8,800 BIO Partnering meetings and an expanded showcase of 2,200 booths, the convention marked its largest edition to date. The event brought together over 600 international delegates from 50 countries, solidifying Taiwan's position as a global hub for biotech innovation and cross-border collaboration.
Taiwan's Vice President, Hsiao Bi-khim, commended the industry's progress and its integration with international standards, emphasizing the country's potential to drive transformative breakthroughs in healthcare and technology.
Johnsee Lee, Chairman of BIO Asia-Taiwan, extended a warm welcome to international delegates from over 50 countries, including the United States, Europe, Canada, Belgium, Netherlands, Australia, Japan, India, Singapore, Philippines and South Korea, with the event drawing over 2,300 participants. In his speech, he emphasized the increasing momentum for collaboration on regulatory harmonization, multi-center clinical trials at international levels, innovation-driven investments and collaborative R&D programs.
BIO Asia-Taiwan is one of Asia's premier gatherings of biotech leaders, innovators, and pioneers, states Kelly Seagraves, Vice President of National Security and International Affairs at BIO. She emphasized that the advancement of biotechnology depends on global collaboration: supporting early-stage research, securing necessary funding, and enhancing the resilience of supply chains. Furthermore, she said the event was a reflection of the remarkable growth momentum in the global life sciences industry.
“The cross-border collaboration is an essential part of this industry, whether it is in supply chains or commercializing early-stage research and development. Taiwan plays an integral role in this transformation. The co-hosting of BIO Asia–Taiwan by BIO and the Taiwan Bio Industry Organization (Taiwan BIO) is a prime example of international cooperation and industry integration” asserted Kelly Seagraves.
The Taiwan Bio Industry Association (Taiwan BIO) serves as a bridge between government and industry, fostering global partnerships and supporting members in navigating the rapidly evolving bioeconomy. Taiwan BIO has also signed multiple Memorandums of Understanding (MoUs) with overseas biotech associations over the past 18 months.
Taiwan's Minister of Health and Welfare Chiu Tai-yuan remarked in his speech that BIO Asia–Taiwan has now become one of the world’s top three biotechnology conventions. He emphasized that Taiwan will continue to position itself as an innovation hub in Asia, focusing on three key areas: technological innovation, regional collaboration, and biotech investment. The government will continue to advance health equity and sustainable care, while deepening efforts in precision medicine, cancer and chronic disease prevention. Through developments in cell therapy, biologics, and smart medical devices, Taiwan aims to further enhance its global visibility and influence in medical technology.
Wu Cheng-wen, Minister of the National Science and Technology Council, stated that the Executive Yuan of the Taiwan government held a special discussion this morning on strategies to integrate semiconductors with industries such as healthcare and agriculture. Going forward, the government will build a comprehensive innovation platform to promote the development of fields including digital therapeutics, smart diagnostics, early cancer screening, and AI-assisted diagnosis. He expressed hope that Taiwan’s industries and its leaders will collaborate with the government to gradually build a national team that can contribute globally in biotech, healthcare, and agriculture.
Taiwan Premier Cho Jung-tai made a special appearance at the opening ceremony, stating that BIO Asia–Taiwan, as a major international gathering, can showcase to the world Taiwan’s potential in the medical and health sectors. He highlighted that Taiwan’s biotech companies have achieved a total revenue of NT$775 billion (US$26 billion), and several Taiwan-developed new drugs have successfully entered global markets, reflecting the country's growing influence in the international biotech arena.
Premier Cho Jung-tai recalled that Minister Wu Cheng-wen presented the “Taiwan Chip-based Industrial Innovation Program”, which aims to further integrate applications such as telecommunications, artificial intelligence, and Big Data to accelerate medical innovation, particularly in precision health and agriculture. He further stated that President Lai Ching-te has established the “Healthy Taiwan Promotion Committee”, which is strengthening cancer screening efforts and has launched a NT$10 billion (US$340 million) fund for cancer drug development. The initiative also emphasizes genetic testing and precision medicine. In addition, the government plans to launch the Long-Term Care 3.0 plan next year. Premier Cho expressed hopes for global collaboration to advance industrial diversification and further enhance Taiwan’s international competitiveness in the healthcare and biotech sectors.
Exhibition Highlights: Biotechnology Innovation and Collaboration Expo
BIO Asia-Taiwan has become one of the world's top three biotechnology conventions, spotlighting Taiwan's role as a center of innovation in Asia. By focusing on technological innovation, regional collaboration, and biotech investment, Taiwan is advancing health equity and sustainable care through precision medicine. In recent years, the nation has demonstrated a strong focus on developing cell therapy, biologics, and smart medical devices to enhance its global influence in medical technology. With many of Taiwan's biotech companies expanding internationally, BIO Asia-Taiwan exemplifies Taiwan's biotech industry dominance, and its potential to serve as a hub for international health and medical development.
The Innovation Forum at the forum showcased cutting-edge themes such as AI-driven drug development, cell therapy and CDMO services, smart healthcare, GLP-1 drugs for cardiovascular disease, weight loss, and diabetes management, as well as antibody-drug conjugates (ADCs). Taiwan aims to establish a comprehensive innovation platform to advance digital therapeutics, smart diagnostics, early cancer screening, and AI-assisted diagnosis as well.
A panel of industry leaders and scholars further evaluated advancements in digital health, neuroimaging, and Alzheimer's treatment, emphasizing Taiwan's potential as a global center for innovation in healthcare and technology.
The Investment Forum brought together prominent global venture capital firms like Illumina Ventures and Syncona, and served as a platform for 45 high-potential companies to present innovations in oncology, cell therapy, and novel drug delivery, paving the way for future M&A and licensing opportunities. The event highlighted progress in digital health investments, breakthrough antibody platforms, and the region's maturing scientific and commercial landscape.
First of its kind, the Regional Collaboration Forums convened representatives from over 10 countries, leading to the formation of the ‘Asia Pacific Regional Biotech Cooperation Working Group’, an initiative aimed to foster ongoing cross-border dialogue, particularly benefiting developing nations in Southeast Asia. For the first time, Taiwan’s Taiwan External Trade Development Council (TAITRA) hosted a Medical Device & Health/Beauty Business Forum during BIO Asia–Taiwan 2025, further expanding international collaboration opportunities.
The exhibition halls featured "Contract Development and Manufacturing Services", "Precision Medicine and Genetic Testing," the "National Pavilion Zone," "Government-Academic Research Zone," and "Industry-Academic Incubation Zone," allowing visitors to gain insights into the biotech industry chain, including R&D, product development, and equipment development. A shift from conventional therapies to advanced therapies, regulatory developments, and precision medicine was predominant in the series, which would lead to continued breakthroughs and transformative developments.
Concurrently, the "BioAsia Expo" was held from July 26th to 29th at Taipei Nangang Exhibition Center Hall 1. This year's event, themed "Global View, Asian Touch," showcased the breakthroughs in new drugs, innovative therapies, and regenerative medicine in Asia and Taiwan, driven by rapid economic development.
Minister of Health and Welfare Chiu Tai-yuan, Chairman of the Asian Biotechnology Conference Lee Jong-hee, and Chairman of the Taiwan Bioindustry Development Association Wu Zhongxun attended the event.
Exhibitors from 19 countries were represented in 12 national pavilions, including the United States, Switzerland, Japan, Australia, Belgium, India, Poland, Austria, the Philippines, and Thailand. A global reach of the gathering was demonstrated by the participation of companies from the UK, China, South Korea, Malaysia, Singapore, Italy, and other nations. Over 700 international specialist companies participated, with strong representation from Australia (24 companies), as well as Japan, the United States, and Canada.
Industry leaders such as Taiwan’s PharmaEssentia, Bora Pharmaceuticals, Taimed Biologics, EirGenix, Foresee Pharmaceuticals, Formosa Laboratories, Alar Pharmaceuticals, EverFortune.ai, and Mycenax, alongside major multinational companies such as Merck, FUJIFILM, Cytiva, BD, Charles River, Lonza, and Labcorp, showcased their latest innovations. During their demonstrations, they provided an overview of cutting-edge technologies and market trends in the global biotech sector.
Eight Taiwan government pavilions, including those of the Ministry of Economic Affairs, Ministry of Health and Welfare, National Science and Technology Council, and National Health Research Institutes, demonstrated their strengths and affirmations.
Ten top academic and research institutions, including China Medical University, National Cheng Kung University, National Tsing Hua University, National Taiwan University, Taipei Medical University, and National Taipei University of Technology, were showcasing their latest innovations.
Exclusive Zones: CDMO, Biopharma, Medtech and Cell and Regenerative Therapies
Taiwan's biotech strengths were celebrated in three predominant zones, offering new opportunities for international collaboration and innovation. Featuring precision medicine, sustainable healthcare, and cutting-edge technologies, the convention showcased the nation's commitment to fostering partnerships and advancing global bioscience
A CDMO Zone brought together leading local and international contract manufacturers, including Bora Pharmaceuticals, EirGenix, TBMC, Formosa Laboratories, Taimed Biologics, Mycenax, Formosa Pharmaceuticals, Genovior Biotech, Amaran Biotech, UBI Pharma, Zillion Fine Chemicals Int'l, and the Taiwan CDMO Alliance, which showcased advanced technology and production capabilities.
The Biopharma & Medtech Zone featured major players including PharmaEssentia, MycoMagic Biotechnology, Golden Biotechnology, Foresee Pharmaceuticals, Wendy International, Orient EuroPharma, Orient Pharma, and APRINOIA Therapeutics, who will present the latest in drug and device R&D.
The Cell and Regenerative Therapies Zone brought together ChainHome Biotech, Integrated Bio, Level Biotechnology, Mitek Lab, Han Biomedical, Cold Spring Biotech, and others, displaying cutting-edge therapies and promising applications.
Collaborations and Strategic Alliances over One-to-One Partnering Program:
BIO Partnering™ — World's Largest Partnering Experience
Collaborations and strategic alliances took center stage at BIO Asia-Taiwan 2025, showcasing the region's role as a global hub for biotech innovation. A diverse array of innovations and business opportunities drove collaborations that positioned the biotechnology sector in Asia as a global center for innovation and partnership.
Business matchmaking remained a signature feature of BIO Asia–Taiwan, and this year was no exception. Over 400 global companies from 29 countries participated in an exclusive partnering program, facilitating more than 8,800 meetings—a 15% increase from the previous year. Business matchmaking remained a signature feature of BIO Asia–Taiwan, and this year was no exception, with companies from 29 countries joining the initiative.
Additionally, countries such as Australia, the US, Canada, and Belgium hosted regional forums and business meetings to explore collaborations with Taiwan’s thriving biomedical sector.
For the first time, Taiwan’s Taiwan External Trade Development Council (TAITRA) hosted a Medical Device & Health/Beauty Business Forum. The sector is projected to generate over US$300 million in business opportunities and thus expanding international collaboration opportunities.
The prime collaborations aimed to strengthen Taiwan's position in the global biotech industry, fostering partnerships that drove innovation and contributed to significant advancements in healthcare and biotechnology.
The partnering forum underscored the industry's strong momentum and dynamic progress. By fostering collaborations, the country seeks to build a team capable of making significant global contributions to biotech and healthcare.
Accolade and Recognitions:
At the opening ceremony, the 2025 BIO Asia Award and Taiwan BIO Awards were presented to honor excellence in the biotech industry. Taiwan’s Premier Cho Jung-tai, BIO Asia–Taiwan Chairman Johnsee Lee, and Taiwan Bio Industry Organization Chairman Lee-Cheng Liu presided over the ceremony, recognizing exemplary industry accomplishments, key contributors and innovators spearheading the momentum.
The Vice President Hsiao Bi-khim, applauded Taiwan's biotech and medical capabilities and encouraged Taiwan to continue to integrate its biotech industry with international standards. The Vice President presented excelling biotech companies with the "Gold Award," "Potential Benchmark Award," "Outstanding New Venture Award," and "Annual Industry Innovation Award." She invited biotech companies from domestic and international markets to engage in active exchanges and collaborations, thereby promoting Taiwan's biotech industry capabilities.
The second annual “BIO Asia Award” recognized outstanding contributions to the Asia-Pacific biotech sector. Raul V. Destura, from the Philippines, was honored for his contributions to infectious disease diagnostics in Southeast Asia and beyond, and Academician Chi-Huey Wong, from Taiwan, was honored for his groundbreaking contributions to scientific innovation. Taiwan's Development Center for Biotechnology (DCB) received the Organization Award. A presentation was delivered by George Hara of Japan, former 2024 winner.
Taiwan BIO Awards were clinched by 15 companies who dominated the center stage. The Outstanding Company category recognized Standard Chem. & Pharm. (TW: 1720) and Grape King Bio (TW: 1707).
In the Emerging Company category, the winners included Orient Pharma (TW: 4166), Genomics BioSci & Tech (TW: 4195), AP Biosciences (TW: 6945), Applied BioCode (TW: 6598), and Synbio Tech (TW: 1295). The Outstanding Startup awards went to HanchorBio (TW: 7827), JelloX Biotech, and Fecula Biotech.
The Innovation Award recognized five groundbreaking advancements: REGENECYTE and HPC Cord Blood by StemCyte (TW: 4178), a Novel Dual Targeted Therapy for Glaucoma developed by the Industrial Technology Research Institute (ITRI), FaceHeart Vitals™ by FaceHeart (TW: 3011), Precision Oriented Peptides (POPs) by CH Biotech R&D (TW: 6534), and Kang Er Dong Pro and Prebiotics by Grape King Bio.
On the whole, Taiwan is driving transformative breakthroughs in healthcare and biotechnology, reinforcing its position as a leader in the international biotech arena. By integrating cross-border collaboration, supporting early-stage research, and enhancing supply chain resilience, the BIO Asia-Taiwan 2025 forum underscored Taiwan's central role as a hub of biotech innovation and global collaboration.
BIO Asia–Taiwan is poised to achieve new milestones in 2026 by expanding its scope to include agricultural biotech and green technology exhibition zones, enhancing satellite activities, and strengthening international collaborations. These efforts align with the vision of fostering a Healthy Asia, reflecting the event's commitment to advancing the biotech industry across the region.
